Sakar Healthcare Ltd
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]
- Market Cap ₹ 714 Cr.
- Current Price ₹ 328
- High / Low ₹ 479 / 249
- Stock P/E 61.2
- Book Value ₹ 118
- Dividend Yield 0.00 %
- ROCE 7.53 %
- ROE 5.36 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 2.77 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.27% over last 3 years.
- Promoter holding has decreased over last 3 years: -20.9%
- Working capital days have increased from 31.2 days to 61.8 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
83 | 95 | 128 | 133 | 153 | |
63 | 72 | 99 | 100 | 115 | |
Operating Profit | 20 | 23 | 29 | 33 | 38 |
OPM % | 24% | 24% | 23% | 25% | 25% |
2 | 1 | 2 | 4 | 3 | |
Interest | 2 | 2 | 3 | 6 | 8 |
Depreciation | 7 | 8 | 10 | 15 | 18 |
Profit before tax | 12 | 13 | 19 | 17 | 16 |
Tax % | 21% | 19% | 20% | 24% | 27% |
10 | 11 | 15 | 13 | 12 | |
EPS in Rs | 6.43 | 6.84 | 8.90 | 6.70 | 5.37 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 17% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 3% |
TTM: | -9% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 41% |
3 Years: | 23% |
1 Year: | 28% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 8% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 15 | 16 | 17 | 19 | 22 |
Reserves | 66 | 83 | 110 | 154 | 236 |
17 | 43 | 93 | 119 | 69 | |
17 | 37 | 47 | 44 | 62 | |
Total Liabilities | 115 | 178 | 268 | 336 | 389 |
66 | 69 | 205 | 267 | 314 | |
CWIP | 13 | 49 | 1 | 6 | 0 |
Investments | 0 | 0 | 7 | 3 | 0 |
36 | 60 | 55 | 60 | 74 | |
Total Assets | 115 | 178 | 268 | 336 | 389 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
19 | 15 | 36 | 33 | 24 | |
-22 | -47 | -90 | -74 | -52 | |
3 | 32 | 55 | 41 | 27 | |
Net Cash Flow | -0 | -0 | -0 | 0 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 36 | 48 | 40 | 60 | 50 |
Inventory Days | 93 | 112 | 69 | 76 | 121 |
Days Payable | 46 | 141 | 149 | 129 | 120 |
Cash Conversion Cycle | 83 | 19 | -39 | 7 | 51 |
Working Capital Days | 41 | 8 | 2 | 30 | 62 |
ROCE % | 13% | 12% | 9% | 8% |
Documents
Announcements
-
Outcome of Board Meeting
6 August 2022 - Sakar Healthcare Limited has informed about Board Meeting held on 06-Aug-2022 to consider financial statements for the period ended June 2022
-
Related Party Transaction
28 May 2022 - Sakar Healthcare Limited has informed about related party transaction for the period ended March 2022
-
Price movement
24 March 2022 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
-
Trading Window
3 April 2019 - Sakar Healthcare Limited has informed regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
-
Updates
1 April 2019 - Sakar Healthcare Limited has informed regarding 'We are pleased to announce the receipt of "In principle approval" for migration of trading shares from SME (EMERGE) …
Annual reports
Concalls
-
Oct 2022TranscriptNotesPPT
Business Overview:[1][2][3]
SHL, certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and the National Drug Authority, provides comprehensive healthcare and pharmaceutical products. Operating in over 50 countries with 292 registered products and 210 more under registration, SHL partners with 70+ overseas distributors. The company also engages in contract manufacturing for leading domestic brands and direct sales in both domestic and export markets.